Cadence Pharmaceuticals Inc (CADX) financial statements (2022 and earlier)

Company profile

Business Address 12481 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments57,40162,072
Cash and cash equivalents55,07558,327
Short-term investments2,3263,745
Restricted cash and investments548640
Receivables9,3006,152
Inventory, net of allowances, customer advances and progress billings8,6466,498
Inventory8,6466,498
Prepaid expense1,902
Prepaid expense and other current assets1,154
Other current assets91
Total current assets:77,88876,516
Noncurrent Assets
Property, plant and equipment2,0601,967
Intangible assets, net (including goodwill)10,74712,090
Intangible assets, net (excluding goodwill)10,74712,090
Restricted cash and investments92 
Other noncurrent assets16
Prepaid expense and other noncurrent assets7,106
Total noncurrent assets:12,91521,163
TOTAL ASSETS:90,80397,679
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities25,76618,765
Accounts payable7,7245,796
Accrued liabilities18,04212,969
Debt10,777 
Asset retirement obligation 750
Deferred revenue and credits 2,234
Other undisclosed current liabilities (750)
Total current liabilities:36,54320,999
Noncurrent Liabilities
Long-term debt and lease obligation18,53828,818
Long-term debt, excluding current maturities18,53828,818
Liabilities, other than long-term debt84451
Other liabilities84451
Total noncurrent liabilities:19,38228,869
Total liabilities:55,92549,868
Stockholders' equity
Stockholders' equity attributable to parent34,87847,811
Common stock99
Additional paid in capital506,819495,458
Accumulated deficit(471,950)(447,656)
Total stockholders' equity:34,87847,811
TOTAL LIABILITIES AND EQUITY:90,80397,679

Income statement (P&L) ($ in thousands)

12/31/2013
12/31/2012
Revenues112,55650,184
Revenue, net112,55650,302
Cost of revenue
(Cost of Goods and Services Sold)
(37,973)(23,419)
Other undisclosed gross profit 163
Gross profit:74,58326,928
Operating expenses(102,885)(103,725)
Other operating income, net441 
Other undisclosed operating income317123
Operating loss:(27,544)(76,674)
Nonoperating income (expense)3,250(4,299)
Other nonoperating income7,64827
Interest and debt expense(4,467)(4,449)
Loss from continuing operations before equity method investments, income taxes:(28,761)(85,422)
Other undisclosed income from continuing operations before income taxes4,4674,449
Net loss available to common stockholders, diluted:(24,294)(80,973)

Comprehensive Income ($ in thousands)

12/31/2013
12/31/2012
Net loss:(24,294)(80,973)
Other comprehensive loss (2)
Comprehensive loss, net of tax, attributable to parent:(24,294)(80,975)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: